Compare Best Buy Co Inc (BBY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Best Buy Co Inc vs TransMedics Group Inc — how do they compare? Best Buy Co Inc trades at $83 (market cap $17.55B), while TransMedics Group Inc trades at $87.11 (market cap $3.10B). The key difference: Best Buy Co Inc is far larger — about 5.7× TransMedics Group Inc's market cap, and Best Buy Co Inc pays a 4.61% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| BBY | TMDX | |
|---|---|---|
Market Cap | $17.55B | $3.10B |
Sector | Consumer Cyclical | Technology |
52-Week High | $90.17 | $150.42 |
52-Week Low | $55.52 | $61.99 |
Enterprise Value | $19.93B | $3.49B |
Dividend Yield | 4.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Best Buy (BBY) trades at $82.99, up 0.68% on the day, with a neutral technical outlook despite bullish moving averages. The company shows strong profitability with 39.1% ROE and 7.88% ROA, though revenue has declined from $51.8B in 2022 to $41.5B in 2025. Recent leadership changes include a new CFO appointment and marketing chief departure, while the company tests smaller store formats to drive growth.
The stock offers modest upside to the $84.31 consensus target with solid fundamentals but faces revenue pressure and leadership transition risks. Positive cash flow trends and consistent earnings beats support the investment case, though competitive retail pressures and macroeconomic headwinds remain concerns.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
